Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common StockGlobeNewsWire • 10/02/20
Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common StockGlobeNewsWire • 09/29/20
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisGlobeNewsWire • 09/29/20
Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisGlobeNewsWire • 09/16/20
Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020GlobeNewsWire • 09/15/20
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDAGlobeNewsWire • 09/08/20
Arcutis Announces Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/11/20
The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisGlobeNewsWire • 08/03/20
Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisGlobeNewsWire • 07/31/20
Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical OfficerGlobeNewsWire • 07/27/20
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisGlobeNewsWire • 07/15/20
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaGlobeNewsWire • 07/13/20
Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisGlobeNewsWire • 06/22/20
Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care ConferenceGlobeNewsWire • 06/10/20
Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and OperationsGlobeNewsWire • 05/27/20
Arcutis Announces First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/20
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand EczemaGlobeNewsWire • 04/21/20
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque PsoriasisGlobeNewsWire • 03/16/20